128 related articles for article (PubMed ID: 36314929)
1. Blood MALT1 deficiency is common and relates to unfavorable induction therapy response and survival profile in acute myeloid leukemia patients.
Geng H; Wang Y; Wang S
Hematology; 2022 Dec; 27(1):1176-1183. PubMed ID: 36314929
[TBL] [Abstract][Full Text] [Related]
2. SUMO specific peptidase 1 decreases after induction treatment, and its reduction predicts lower disease risk, better treatment response, longer survival of acute myeloid leukemia.
Liu J; Li Y; Zhang G
Scand J Clin Lab Invest; 2023 Sep; 83(5):283-289. PubMed ID: 37405376
[TBL] [Abstract][Full Text] [Related]
3. SETD2 detection may reveal response to induction therapy and survival profile in acute myeloid leukemia patients.
Liu H
Hematology; 2023 Dec; 28(1):2161194. PubMed ID: 36607144
[TBL] [Abstract][Full Text] [Related]
4. Potentiality of Protein phosphatase Mg
Yu M; Hu J; He D; Chen Q; Liu S; Zhu X; Li B
J Clin Lab Anal; 2020 May; 34(5):e23171. PubMed ID: 31901183
[TBL] [Abstract][Full Text] [Related]
5. MALT1 positively relates to Th17 cells, inflammation/activity degree, and its decrement along with treatment reflects TNF inhibitor response in ankylosing spondylitis patients.
Yuan J; Xiang L; Wang F; Zhang L; Liu G; Chang X; Zhang A; Tao Y
J Clin Lab Anal; 2022 Jul; 36(7):e24472. PubMed ID: 35622982
[TBL] [Abstract][Full Text] [Related]
6. Circular RNA SPI1 expression before and after induction therapy and its correlation with clinical features, treatment response, and survival of acute myeloid leukemia patients.
Xiong T; Xia L; Song Q
J Clin Lab Anal; 2023 Feb; 37(3):e24835. PubMed ID: 36644997
[TBL] [Abstract][Full Text] [Related]
7. Mucosa-associated lymphoid tissue lymphoma translocation protein 1 in rheumatoid arthritis: Longitudinal change after treatment and correlation with treatment efficacy of tumor necrosis factor inhibitors.
Wang F; Liu G; Xiang L; Yuan J; Tao Y; Zhang L; Zhang A; Chang X
J Clin Lab Anal; 2022 Jun; 36(6):e24449. PubMed ID: 35500150
[TBL] [Abstract][Full Text] [Related]
8. Retraction: The
Zeng P; Chai Y; You C; Yue L; Wu C; Chen H; Li L; Li J; Liu H; Zhang Y; Cao T; Li Y; Hu W
Turk J Haematol; 2022 Aug; 39(3):188-195. PubMed ID: 35657175
[TBL] [Abstract][Full Text] [Related]
9. [Clinical features and early treatment effects in intermediate risk and poor risk acute myeloid leukemia with EVI1 positive].
Duan WB; Gong LZ; Jia JS; Zhu HH; Zhao XS; Jiang Q; Zhao T; Wang J; Qin YZ; Huang XJ; Jiang H
Beijing Da Xue Xue Bao Yi Xue Ban; 2017 Dec; 49(6):990-995. PubMed ID: 29263470
[TBL] [Abstract][Full Text] [Related]
10. Impact of induction chemotherapy with intermediate-dosed cytarabine and subsequent allogeneic stem cell transplantation on the outcome of high-risk acute myeloid leukemia.
Fleischmann M; Schnetzke U; Frietsch JJ; Sayer HG; Schrenk K; Hammersen J; Glaser A; Hilgendorf I; Hochhaus A; Scholl S
J Cancer Res Clin Oncol; 2022 Jun; 148(6):1481-1492. PubMed ID: 34297206
[TBL] [Abstract][Full Text] [Related]
11. IncRNA MVIH correlates with disease features, predicts treatment response and survival in pediatric acute myeloid leukemia.
Xue H; Gao H; Xia H; Li S; Li N; Gao C; Duan Y; Ren Y; Zhang H; Liu J; Gao W
J Clin Lab Anal; 2021 Apr; 35(4):e23739. PubMed ID: 33704838
[TBL] [Abstract][Full Text] [Related]
12. Predictive value of integrin α7 for acute myeloid leukemia risk and its correlation with prognosis in acute myeloid leukemia patients.
Zeng M; Ding S; Zhang H; Huang Q; Ren Y; Guo P
J Clin Lab Anal; 2020 Apr; 34(4):e23151. PubMed ID: 31855276
[TBL] [Abstract][Full Text] [Related]
13. Peripheral blood blast clearance is an independent prognostic factor for survival and response to acute myeloid leukemia induction chemotherapy.
Short NJ; Benton CB; Chen HC; Qiu P; Gu L; Pierce S; Brandt M; Maiti A; Min TL; Naqvi K; Quintas-Cardama A; Konopleva M; Kadia T; Cortes J; Garcia-Manero G; Ravandi F; Jabbour E; Kantarjian H; Andreeff M
Am J Hematol; 2016 Dec; 91(12):1221-1226. PubMed ID: 27474808
[TBL] [Abstract][Full Text] [Related]
14. Linkage of Blood MALT1 with CD4+ T Cell Subset, Inflammation, Lipid, and Its Potency as a Biomarker for Predicting Major Adverse Cardiovascular Events in Coronary Heart Disease Patients.
Zhang L; Li J; Yang Z; Wang S; Liu J; Luan S; Tian G
Ann Clin Lab Sci; 2023 Jul; 53(4):507-515. PubMed ID: 37625844
[TBL] [Abstract][Full Text] [Related]
15. The prognostic impact of tet oncogene family member 2 mutations in patients with acute myeloid leukemia: a systematic-review and meta-analysis.
Wang R; Gao X; Yu L
BMC Cancer; 2019 Apr; 19(1):389. PubMed ID: 31023266
[TBL] [Abstract][Full Text] [Related]
16. Long non-coding RNA taurine-upregulated gene 1 correlates with unfavorable prognosis in patients with refractory or relapsed acute myeloid leukemia treated by purine analogue based chemotherapy regimens.
Luo W; Yu H; Zou X; Ni X; Wei J
Cancer Biomark; 2018; 23(4):485-494. PubMed ID: 30347595
[TBL] [Abstract][Full Text] [Related]
17. [Biological properties and sensitivity to induction therapy of differentiated cells expressing atypical immunophenotype in acute leukemia of children].
Pituch-Noworolska A
Folia Med Cracov; 2001; 42(3):5-80. PubMed ID: 12353422
[TBL] [Abstract][Full Text] [Related]
18. Aberrant blood MALT1 and its relevance with multiple organic dysfunctions, T helper cells, inflammation, and mortality risk of sepsis patients.
Wang Y; Huang Q; He F
J Clin Lab Anal; 2022 Apr; 36(4):e24331. PubMed ID: 35262976
[TBL] [Abstract][Full Text] [Related]
19. Standard-Intensity Induction and Intermediate/High-Dose Cytarabine Consolidation Can Improve Survival for Elderly Patients with Newly Diagnosed Acute Myeloid Leukemia: A Retrospective Cohort Study.
Wang L; Zhao N; Zhou L; Tong J; Xue L; Zhang L; Han Y; Wang X; Geng L; Tang B; Liu H; Zhu W; Cai X; Liu X; Zhu X; Sun Z; Zheng C
Clin Interv Aging; 2022; 17():55-64. PubMed ID: 35082491
[TBL] [Abstract][Full Text] [Related]
20. Long non‑coding RNA ANRIL is a potential indicator of disease progression and poor prognosis in acute myeloid leukemia.
Tan Z; Zhu K; Yin Y; Luo Z
Mol Med Rep; 2021 Feb; 23(2):. PubMed ID: 33300059
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
